Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume 21, Issue S1, Pages 39-51
Publisher
Wiley
Online
2019-04-19
DOI
10.1111/dom.13636
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial
- (2018) Marja-Riitta Taskinen et al. ATHEROSCLEROSIS
- Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Pre-Specified Secondary End Points in ORION 1
- (2018) Kausik K. Ray et al. CIRCULATION
- Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: the BERSON clinical trial
- (2018) Alberto J. Lorenzatti et al. CLINICAL CARDIOLOGY
- PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate
- (2018) Mikaël Croyal et al. CLINICAL SCIENCE
- Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials
- (2018) Om P. Ganda et al. DIABETES OBESITY & METABOLISM
- Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial
- (2018) Kausik K. Ray et al. DIABETES OBESITY & METABOLISM
- Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis
- (2018) Ye-Xuan Cao et al. DIABETES OBESITY & METABOLISM
- PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor
- (2018) Lorenzo Da Dalt et al. EUROPEAN HEART JOURNAL
- Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics
- (2018) Gerald F Watts et al. EUROPEAN HEART JOURNAL
- Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk
- (2018) Benoit J. Arsenault et al. Journal of Clinical Lipidology
- Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?
- (2018) Wieneke Dijk et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies
- (2018) Henry N. Ginsberg et al. Diabetes Therapy
- Efficacy and Safety of Alirocumab in Individuals with Diabetes Mellitus: Pooled Analyses from Five Placebo-Controlled Phase 3 Studies
- (2018) Henry N. Ginsberg et al. Diabetes Therapy
- Alirocumab safety in people with and without diabetes mellitus: pooled data from 14 ODYSSEY trials
- (2018) L. A. Leiter et al. DIABETIC MEDICINE
- Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2018) Aidin Rawshani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: Effects of glycemic control
- (2018) Dragana Bojanin et al. ATHEROSCLEROSIS
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
- (2018) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response
- (2017) Teik Chye Ooi et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
- (2017) Robert P Giugliano et al. LANCET
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
- (2017) Aidin Rawshani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women
- (2017) Amy E. Levenson et al. PEDIATRIC DIABETES
- Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
- (2017) Marc S Sabatine et al. Lancet Diabetes & Endocrinology
- PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
- (2017) Amand F Schmidt et al. Lancet Diabetes & Endocrinology
- Long-term Low-Density Lipoprotein Cholesterol–Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia
- (2017) Michael J. Koren et al. JAMA Cardiology
- Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus
- (2017) Robert P. Giugliano et al. CIRCULATION
- Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopy—Brief ReportHighlights
- (2016) Rutger Verbeek et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in four phase 3 odyssey trials with/without statin background
- (2016) J.G. Robinson et al. ATHEROSCLEROSIS
- Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy HumansClinical Perspective
- (2016) Gissette Reyes-Soffer et al. CIRCULATION
- Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein MetabolismClinical Perspective
- (2016) Gerald F. Watts et al. CIRCULATION
- Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes
- (2016) Stéphanie Laugier-Robiolle et al. DIABETES OBESITY & METABOLISM
- Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome
- (2016) Dirk J. Blom et al. DIABETES OBESITY & METABOLISM
- No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies
- (2016) Helen M. Colhoun et al. EUROPEAN HEART JOURNAL
- Association Between Low-Density Lipoprotein Cholesterol–Lowering Genetic Variants and Risk of Type 2 Diabetes
- (2016) Luca A. Lotta et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology
- (2016) Børge G. Nordestgaard et al. JOURNAL OF LIPID RESEARCH
- Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
- (2016) Brian A. Ference et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacological management of diabetic dyslipidemia
- (2016) T. D. Filippatos et al. Expert Review of Clinical Pharmacology
- Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data
- (2016) Naveed Sattar et al. Lancet Diabetes & Endocrinology
- Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes
- (2016) Jon White et al. JAMA Cardiology
- Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9Significance
- (2015) Ji Miao et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk
- (2015) Montse Guardiola et al. CLINICAL SCIENCE
- Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state
- (2015) Dick C. Chan et al. CLINICAL SCIENCE
- Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels
- (2015) Eli M. Roth et al. CLINICAL THERAPEUTICS
- Positive correlation of plasma PCSK9 levels with HbA1cin patients with type 2 diabetes
- (2015) Sheng-Hua Yang et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Pathophysiology of diabetic dyslipidaemia: where are we?
- (2015) Bruno Vergès DIABETOLOGIA
- Association Between Familial Hypercholesterolemia and Prevalence of Type 2 Diabetes Mellitus
- (2015) Joost Besseling et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials
- (2015) Daniel I Swerdlow et al. LANCET
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- PCSK9
- (2014) Nabil G. Seidah et al. CIRCULATION RESEARCH
- The effect of insulin on circulating PCSK9 in postmenopausal obese women
- (2014) Zuhier Awan et al. CLINICAL BIOCHEMISTRY
- Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis
- (2014) Sebhat Erqou et al. DIABETOLOGIA
- Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets
- (2013) Bertrand Cariou et al. Nutrition & Metabolism
- Meta-Analysis of Comparison of Effectiveness of Lowering Apolipoprotein B Versus Low-Density Lipoprotein Cholesterol and Nonhigh-Density Lipoprotein Cholesterol for Cardiovascular Risk Reduction in Randomized Trials
- (2012) Jennifer G. Robinson et al. AMERICAN JOURNAL OF CARDIOLOGY
- Proprotein Convertase Subtilisin/Kexin Type 9 Interacts With Apolipoprotein B and Prevents Its Intracellular Degradation, Irrespective of the Low-Density Lipoprotein Receptor
- (2012) Hua Sun et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial
- (2012) Paul M Ridker et al. LANCET
- Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study
- (2011) M.C.G.J. Brouwers et al. ATHEROSCLEROSIS
- Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes
- (2011) Bruno Vergès et al. ATHEROSCLEROSIS
- Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges
- (2011) Uchechukwu K. Sampson et al. Current Atherosclerosis Reports
- PCSK9 LNA Antisense Oligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman Primates
- (2011) Marie W Lindholm et al. MOLECULAR THERAPY
- Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people
- (2011) Shelby Sullivan et al. Translational Research
- Plasma proprotein convertase subtilisin–kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients
- (2010) Paul J.W.H. Kappelle et al. ATHEROSCLEROSIS
- Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans
- (2010) Jeffrey D. Browning et al. JOURNAL OF LIPID RESEARCH
- Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia
- (2009) Cédric Le May et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The LDL Receptor
- (2009) Joseph L. Goldstein et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- PCSK9 is expressed in pancreatic δ-cells and does not alter insulin secretion
- (2009) Cédric Langhi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Plasma PCSK9 Is Associated with Age, Sex, and Multiple Metabolic Markers in a Population-Based Sample of Children and Adolescents
- (2009) A. Baass et al. CLINICAL CHEMISTRY
- PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities
- (2009) Majambu Mbikay et al. FEBS LETTERS
- Genetic and Metabolic Determinants of Plasma PCSK9 Levels
- (2009) Susan G. Lakoski et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Selective versus Total Insulin Resistance: A Pathogenic Paradox
- (2008) Michael S. Brown et al. Cell Metabolism
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More